Saved Results

No results saved yet.

Enter a patient name and hit Save on a result.

Clinical calculator summary

FIGO GTN Risk Score

The FIGO (2000) scoring system divides patients with Gestational Trophoblastic Neoplasia (GTN) into low-risk and high-risk groups.

Evidence-based context for fast calculator use

Purpose:
FIGO GTN Risk Score stratifies gestational trophoblastic neoplasia into low or high risk to guide single-agent vs multi-agent chemotherapy.
Population:
patients undergoing ovarian, cervical, endometrial, or gestational-trophoblastic risk and staging assessment
Factors:
Age, Antecedent Pregnancy, Interval from Index Pregnancy, Pre-treatment hCG, Largest Tumor Size, Site of Metastases, Number of Metastases, Previous Failed Chemotherapy
Reference:
FIGO Oncology Committee. FIGO staging for gestational trophoblastic neoplasia 2000. Int J Gynaecol Obstet. 2002;77(3):285-287.
HomeFIGO GTN Risk Score
Pin your most used calculators here by clicking the star in the dropdown.

FIGO GTN Risk Score

Clinical Context & Background

The FIGO (2000) scoring system divides patients with Gestational Trophoblastic Neoplasia (GTN) into low-risk and high-risk groups. This stratification determines whether single-agent chemotherapy (Methotrexate/Actinomycin D) or multi-agent chemotherapy (EMA-CO) is indicated. A score of 0-6 is Low Risk; ≥7 is High Risk.
Primary Source EvidenceFIGO Oncology Committee. FIGO staging for gestational trophoblastic neoplasia 2000. Int J Gynaecol Obstet. 2002;77(3):285-287.
Formula Logic
Sum of weighted risk factors (0-4 points each).

Reference Data

Total ScoreRisk GroupTreatment
0 - 6Low RiskSingle-agent chemotherapy
≥ 7High RiskMulti-agent chemotherapy

Clinical Workflow

Use, Interpret, And Continue The Patient Pathway

Expand for workflow guidance, limitations, examples, and related next steps.

When To Use

  • Use FIGO GTN Risk Score when fIGO GTN Risk Score stratifies gestational trophoblastic neoplasia into low or high risk to guide single-agent vs multi-agent chemotherapy.
  • Confirm that the patient, diagnosis, disease phase, and available inputs match the cited model before calculation.

How To Interpret

  • Interpret the displayed result using the calculator-specific formula and reference table, spanning 0 - 6 through ≥ 7.
  • A boundary result should prompt input verification and clinical review rather than false precision.

What To Do Next

  • Confirm organ site, pathology, menopausal or postoperative context, imaging, biomarker assay, and specialist referral pathway.
  • Document the inputs, result, timing, and clinical context so the assessment can be reproduced.

Limitations

  • Adnexal-mass, cervical postoperative, endometrial, and ovarian cytoreduction models answer different clinical questions.
  • The result supports clinician judgment and does not independently determine treatment.

Validated Population

patients undergoing ovarian, cervical, endometrial, or gestational-trophoblastic risk and staging assessment

How to apply this result

For a representative case, verify Age, Antecedent Pregnancy, Interval from Index Pregnancy, calculate the result, and confirm that its classification matches the highlighted reference band before continuing the disease-specific pathway.

Gynecologic Oncology hubContinue to related calculators and clinical workflow resources.

Share This Calculator

Share:

Related Tools

RMI (Risk of Malignancy Index)ROMA Score (Ovarian)AGO Score (DESKTOP)

Frequently Asked Questions

When should FIGO GTN Risk Score be used?

Use it for patients undergoing ovarian, cervical, endometrial, or gestational-trophoblastic risk and staging assessment when all required inputs and the intended clinical setting are confirmed.

Can FIGO GTN Risk Score determine treatment by itself?

No. Interpret the result with the cited evidence, complete clinical assessment, current guidelines, and patient-specific goals.

Evidence-based oncology decision support. Verify with clinical guidelines.